Amoxicillin/clavulanic acid
combination drug
Amoxicillin/clavulanic acid, also known as co-amoxiclav or amox-clav, sold under the brand names Augmentin, and Ranclav among others, is an antibiotic medication used for the treatment of a number of bacterial infections. It is a combination consisting of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor. It is specifically used for otitis media, streptococcal pharyngitis, pneumonia, cellulitis, urinary tract infections, and animal bites. It can be administered orally or intravenously.
Common side effects include diarrhea, vomiting, and allergic reactions. It also increases the risk of yeast infections, headaches, and blood clotting problems. It is not recommended in people with a history of a penicillin allergy. It is relatively safe for use during pregnancy.
Amoxicillin/clavulanic acid was approved for medical use in the United States in 1984. It is on the World Health Organization's List of Essential Medicines.
The public source identifies “Amoxicillin/clavulanic acid” as combination drug. This brief keeps that definition visible, then builds a research path around Amoxicillin, clavulanic and acid.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Amoxicillin/clavulanic acid”, the useful work is to connect “combination drug” to the records capable of establishing context and consequence.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Sep 11, 2026. The linked authority identifier is Q2870929. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1984.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Amoxicillin/clavulanic acid”, its source revision and the description used here.
- Expand the search: follow Amoxicillin/clavulanic acid primary sources, Amoxicillin/clavulanic acid archive and Amoxicillin research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Amoxicillin/clavulanic acid”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Amoxicillin/clavulanic acid” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.